• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Tag: market exclusivity

Dutch Health Care Institute Says No to Medicines Pirate

Ellen 't Hoen - March 29, 2021

EU Review of Pharmaceutical Incentives: Recommendations for Change

Ellen 't Hoen - June 3, 2019

Time to put a stop to the abuse of orphan drug...

Ellen 't Hoen - January 9, 2019

Dutch health insurance company Menzis takes AstraZeneca to court over patent...

Ellen 't Hoen - September 20, 2018

European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to...

Ellen 't Hoen - May 21, 2018

Recent Posts

  • WTO Covid-19 TRIPS Decision: Some observations
  • Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
  • The US NIH will share technology with WHO to fight the pandemic
  • With technology transfer, 120 companies in low- and middle-income countries could manufacture mRNA vaccines

Posts by Subject

Access to Medicines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine Data exclusivity Delinkage DNDi essential medicines list European Commission European Union evergreening Fair Pricing Gilead Hepatitis C IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir SPC The Netherlands TRIPS Council TRIPS flexibilities TRIPS Waiver Truvada vaccines WHO WIPO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok